Biothrax: Clinical Trials

11 trials of Biothrax, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 4 Phase 1, 3 Phase 2, 2 Phase 3, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 23Completed 3
Phase 32Completed 2
Phase 42Completed 2

Follow Biothrax: new trials by email Literature Review of Biothrax trials Research Report on Biothrax

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN - Anthrax
Phase 1CompletedBlueWillow Biologics842020-01-082022-05-18
VELOCITY: An Anthrax Vaccine Clinical Study
AV7909, BioThrax - Anthrax
Phase 3CompletedEmergent BioSolutions36892019-03-112026-05-06
BARDA Securing Anthrax Immunity For the Elderly
BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo) - Anthrax
Phase 2CompletedBiomedical Advanced Research and Development Authority3052018-05-092020-07-21
NasoShield Study of Safety and Immunogenicity
NasoShield, BioThrax, Placebo - Healthy Volunteers
Phase 1CompletedAltimmune, Inc.1452018-01-182025-06-24
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
AVA, Ad4-PA-1, Ad4-PA-GPI-1 - Anthrax Infection
Phase 1CompletedEmergent BioSolutions1202013-11-012024-03-18
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
AV7909, BioThrax - Anthrax
Phase 2CompletedEmergent BioSolutions1682013-01-012024-03-18
Ciprofloxacin BioThrax Co-Administration Study
BioThrax, Ciprofloxacin - Anthrax
Phase 2CompletedEmergent BioSolutions1542012-12-012025-06-15
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
BioThrax® - Bacillus Anthracis (Anthrax)
Phase 4CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3282012-07-012014-05-28
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
BioThrax - Anthrax
Phase 3CompletedEmergent BioSolutions2002011-11-012024-04-09
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
BioThrax, AV7909 Formulation 1, AV7909 Formulation 2 - Bacillus Anthracis (Anthrax) Infection
Phase 1CompletedEmergent BioSolutions1052010-12-012024-03-18
Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change
Anthrax Vaccine Adsorbed, Saline injection - Healthy
Phase 4CompletedCenters for Disease Control and Prevention15642002-05-012024-05-29

Conditions studied

Anthrax (11)  ·  Bacillaceae Infections (1)  ·  Bacterial Infections (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Infections (1)

Sponsors

Emergent BioSolutions (6)  ·  Altimmune, Inc. (1)  ·  Biomedical Advanced Research and Development Authority (1)  ·  BlueWillow Biologics (1)  ·  Centers for Disease Control and Prevention (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

United States (11)

Top investigators

Robert Hopkins, MD, MPH, TM (2)  ·  Carlos Fierro, MD (1)  ·  Cynthia Strout, MD (1)  ·  Derek Muse, MD (1)  ·  Edward Bernton, MD (1)  ·  Emanuel DeNoia, MD (1)  ·  Gideon Akintunde, MD (1)  ·  Gurdyal Kalsi, MD, MTOPRA (1)  ·  Jakub Simon, MD (1)  ·  Jennifer Wright, DVM (1)  ·  Marc Gurwith, MD (1)  ·  Mo Elsafy, MD, MSc (1)  ·  Stephan Sharp, MD (1)

Results publications

PMID 21368772, PMID 23701746, PMID 23741398, PMID 24373307, PMID 26865594, PMID 33129609, PMID 38352727, PMID 41401704